Management of connective tissue disease-associated interstitial lung disease

Rheumatic Disease Clinics of North America

Volumn 41, Issue 2, 2015, Pages 279-294

  Chartrand, Sandra ^a,b   Fischer, Aryeh ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Collagen vascular disease; Connective tissue disease; Interstitial lung disease; Interstitial pneumonia; Management; Pulmonary fibrosis; Treatment

Indexed keywords

AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NINTEDANIB; PIRFENIDONE; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS;

BONE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; ESOPHAGUS FUNCTION DISORDER; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; HEART REHABILITATION; HUMAN; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG TRANSPLANTATION; MYOSITIS; OXYGEN THERAPY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING CESSATION; SYNOVITIS; TREATMENT DURATION; TREATMENT INDICATION; COMPLICATION; DISEASE MANAGEMENT; LUNG DISEASES, INTERSTITIAL;

CONNECTIVE TISSUE DISEASES; DISEASE MANAGEMENT; HUMANS; LUNG DISEASES, INTERSTITIAL;

EID: 84926216361     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.01.002     Document Type: Review

References (88)

1. Roubille C., Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014, 43(5):613-626.
2. Kremer J.M., Alarcon G.S., Weinblatt M.E., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997, 40(10):1829-1837.
3. Golden M.R., Katz R.S., Balk R.A., et al. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. JRheumatol 1995, 22(6):1043-1047.
4. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5(10):578-582.
5. Karampetsou M.P., Liossis S.N., Sfikakis P.P. TNF-alpha antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010, 103(12):917-928.
6. Dixon W.G., Hyrich K.L., Watson K.D., et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010, 69(6):1086-1091.
7. Takeuchi T., Tatsuki Y., Nogami Y., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67(2):189-194.
8. Koike T., Harigai M., Inokuma S., et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. JRheumatol 2009, 36(5):898-906.
9. Panopoulos S.T., Sfikakis P.P. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011, 17(5):362-367.
10. Palmer E., Kelly C., Nisar M., et al. Rheumatoid-arthritis-related interstitial lung disease: association between biologic therapy and survival. Rheumatology (Oxford) 2014, 53(9):1676-1682.
11. Nakashita T., Ando K., Kaneko N., et al. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open 2014, 4(8):e005615.
12. Ando K., Motojima S., Doi T., et al. Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. Respir Investig 2013, 51(2):69-75.
13. Horai Y., Isomoto E., Koga T., et al. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Mod Rheumatol 2013, 23(1):190-194.
14. Steen V.D., Medsger T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998, 41(9):1613-1619.
15. Collard H.R., Ryu J.H., Douglas W.W., et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004, 125(6):2169-2174.
16. Raghu G., Anstrom K.J., King T.E., et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. NEngl J Med 2012, 366(21):1968-1977.
17. Silver R.M., Warrick J.H., Kinsella M.B., et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. JRheumatol 1993, 20(5):838-844.
18. Schnabel A., Reuter M., Gross W.L. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998, 41(7):1215-1220.
19. Akesson A., Scheja A., Lundin A., et al. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994, 37(5):729-735.
20. White B., Moore W.C., Wigley F.M., et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132(12):947-954.
21. Steen V.D., Lanz J.K., Conte C., et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994, 37(9):1290-1296.
22. Tashkin D.P., Elashoff R., Clements P.J., et al. Cyclophosphamide versus placebo in scleroderma lung disease. NEngl J Med 2006, 354(25):2655-2666.
23. Tashkin D.P., Elashoff R., Clements P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007, 176(10):1026-1034.
24. Roth M.D., Tseng C.H., Clements P.J., et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011, 63(9):2797-2808.
25. Hoyles R.K., Ellis R.W., Wellsbury J., et al. Amulticenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54(12):3962-3970.
26. Mira-Avendano I.C., Parambil J.G., Yadav R., et al. Aretrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 2013, 107(6):890-896.
27. Yamasaki Y., Yamada H., Yamasaki M., et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007, 46(1):124-130.
28. Berezne A., Ranque B., Valeyre D., et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. JRheumatol 2008, 35(6):1064-1072.
29. Dheda K., Lalloo U.G., Cassim B., et al. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004, 23(4):306-309.
30. Poormoghim H., Rezaei N., Sheidaie Z., et al. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study. Rheumatol Int 2014, 34(12):1691-1699.
31. Deheinzelin D., Capelozzi V.L., Kairalla R.A., et al. Interstitial lung disease in primary Sjogren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 1996, 154(3 Pt 1):794-799.
32. Swigris J.J., Olson A.L., Fischer A., et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006, 130(1):30-36.
33. Gerbino A.J., Goss C.H., Molitor J.A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008, 133(2):455-460.
34. Liossis S.N., Bounas A., Andonopoulos A.P. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006, 45(8):1005-1008.
35. Fischer A., Brown K.K., Du Bois R.M., et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. JRheumatol 2013, 40(5):640-646.
36. Harigai M., Hara M., Kamatani N., et al. Nation-wide survey for the treatment with cyclosporin A of interstitial pneumonia associated with collagen diseases. Ryumachi 1999, 39(6):819-828.
37. Cavagna L., Caporali R., Abdi-Ali L., et al. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. JRheumatol 2013, 40(4):484-492.
38. Wilkes M.R., Sereika S.M., Fertig N., et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005, 52(8):2439-2446.
39. Takada K., Nagasaka K., Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005, 38(5):383-392.
40. Ochi S., Nanki T., Takada K., et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005, 23(5):707-710.
41. Oddis C.V., Sciurba F.C., Elmagd K.A., et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999, 353(9166):1762-1763.
42. Kurita T., Yasuda S., Oba K., et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford) 2015, 54:39-44.
43. Keir G.J., Maher T.M., Hansell D.M., et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012, 40(3):641-648.
44. Keir G.J., Maher T.M., Ming D., et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014, 19:353-359.
45. Dodds N.L., Lamb H., Mayers L., et al. Rituximab therapy for refractory interstitial lung disease unresponsive to conventional immunosuppression: a case series. Am J Respir Crit Care Med 2014, 189:A1451.
46. Lafyatis R., Kissin E., York M., et al. Bcell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009, 60(2):578-583.
47. Daoussis D., Liossis S.N., Tsamandas A.C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010, 49(2):271-280.
48. Daoussis D., Liossis S.N., Tsamandas A.C., et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012, 30(2 Suppl 71):S17-S22.
49. Vandenbroucke E., Grutters J.C., Altenburg J., et al. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009, 29(12):1499-1502.
50. Sem M., Molberg O., Lund M.B., et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009, 48(8):968-971.
51. Unger L., Kampf S., Luthke K., et al. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford) 2014, 53(9):1630-1638.
52. Matteson E., Bongartz T., Ryu J., et al. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmune Dis 2012, 2(3):53-58.
53. Seibold J.R., Denton C.P., Furst D.E., et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010, 62(7):2101-2108.
54. Noble P.W., Albera C., Bradford W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377(9779):1760-1769.
55. King T.E., Bradford W.Z., Castro-Bernardini S., et al. Aphase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. NEngl J Med 2014, 370(22):2083-2092.
56. Richeldi L., du Bois R.M., Raghu G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. NEngl J Med 2014, 370(22):2071-2082.
57. Johnson-Warrington V., Williams J., Bankart J., et al. Pulmonary rehabilitation and interstitial lung disease: aiding the referral decision. JCardiopulm Rehabil Prev 2013, 33(3):189-195.
58. Visca D., Montgomery A., de Lauretis A., et al. Ambulatory oxygen in interstitial lung disease. Eur Respir J 2011, 38(4):987-990.
59. Ntoumazios S.K., Voulgari P.V., Potsis K., et al. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum 2006, 36(3):173-181.
60. Miura Y., Fukuda K., Maeda T., et al. Gastroesophageal reflux disease in patients with rheumatoid arthritis. Mod Rheumatol 2014, 24(2):291-295.
61. Bredenoord A.J., Pandolfino J.E., Smout A.J. Gastro-oesophageal reflux disease. Lancet 2013, 381(9881):1933-1942.
62. Weinstein W.M., Kadell B.M. The gastrointestinal tract in systemic sclerosis. Systemic sclerosis 2004, vol. xvii:293-308. Lippincott Williams & Wilkins, Philadelphia. 2nd edition.
63. Nathan S.D., Hassoun P.M. Pulmonary hypertension due to lung disease and/or hypoxia. Clin Chest Med 2013, 34(4):695-705.
64. Ahmed S., Palevsky H.I. Pulmonary arterial hypertension related to connective tissue disease: a review. Rheum Dis Clin North Am 2014, 40(1):103-124.
65. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003, 167(5):735-740.
66. Steen V., Medsger T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48(2):516-522.
67. Allanore Y., Borderie D., Avouac J., et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008, 58(1):284-291.
68. Miller L., Chartrand S., Koenig M., et al. Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a French Canadian cohort. Scand J Rheumatol 2014, 43(4):314-323.
69. Olschewski H., Ghofrani H.A., Walmrath D., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999, 160(2):600-607.
70. Shapiro S. Management of pulmonary hypertension resulting from interstitial lung disease. Curr Opin Pulm Med 2003, 9(5):426-430.
71. Corte T.J., Keir G.J., Dimopoulos K., et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2014, 190(2):208-217.
72. Solomon J.J., Fischer A. Connective tissue disease-associated interstitial lung disease: a focused review. JIntensive Care Med 2013, [Epub ahead of print].
73. Suda T., Kaida Y., Nakamura Y., et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 2009, 103(6):846-853.
74. Tachikawa R., Tomii K., Ueda H., et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic. Respiration 2012, 83(1):20-27.
75. Boussaud V., Mal H., Trinquart L., et al. One-year experience with high-emergency lung transplantation in France. Transplantation 2012, 93(10):1058-1063.
76. Bridges C.B., Coyne-Beasley T. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2014. Ann Intern Med 2014, 160(3):190.
77. Bombardier C., Hazlewood G.S., Akhavan P., et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. JRheumatol 2012, 39(8):1583-1602.
78. van Assen S., Agmon-Levin N., Elkayam O., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70(3):414-422.
79. Veetil B.M., Myasoedova E., Matteson E.L., et al. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res 2013, 65(6):854-861.
80. Zhang J., Delzell E., Xie F., et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther 2011, 13(5):R174.
81. Sepkowitz K.A. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002, 34(8):1098-1107.
82. Iikuni N., Kitahama M., Ohta S., et al. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol 2006, 16(5):282-288.
83. Sowden E., Carmichael A.J. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis 2004, 4:42.
84. Vananuvat P., Suwannalai P., Sungkanuparph S., et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 2011, 41(3):497-502.
85. Van Staa T.P., Leufkens H.G., Abenhaim L., et al. Use of oral corticosteroids and risk of fractures. June, 2000. JBone Miner Res 2005, 20(8):1487-1494. [discussion: 1486].
86. Grossman J.M., Gordon R., Ranganath V.K., et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010, 62(11):1515-1526.
87. Schachna L., Medsger T.A., Dauber J.H., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006, 54(12):3954-3961.
88. Saggar R., Khanna D., Furst D.E., et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J 2010, 36(4):893-900.